Sight Sciences Q2 revenue $23.4M (+20% YoY); raises FY2026 revenue guidance to $88-92M

Sight Sciences, Inc.

Q2 revenue $23.4M (+20% YoY); IG $20.7M (+8%), IDE record $2.7M (+704%).
Net loss improved to $4.4M ($0.08 loss per share) from $11.9M ($0.23) YoY.
Raised FY2026 revenue guidance to $88-92M (prior $83-89M); reduced adjusted opex guidance to $92-94M.
Cash usage $5.2M in Q2, down 28% YoY; cash $79.8M; debt $40M.
FDA 510(k) clearance for OMNI Ultra; Aetna coverage for implant-free glaucoma procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.